BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
bbio · stock forecast · 26 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 26 Wall Street analysts in the past 3 months
Buy
26 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$157
Consensus
$105
+55.6% upside
Low
$83.00
Median: $100 · Last Close: $67.61
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$105.21
55.6% upside
High Target
$157
132.2%
Low Target
$83
22.8%
Current Price
$67.61
as of today
Based on analyst price targets, the BBIO stock price prediction for the next 12 months ranges from $83 to $157. The consensus BBIO price forecast of $105.21 implies 55.6% upside from the current price of $67.61.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $66.83 | ↓ 1.16% |
1-day model range: $66.51–$67.15. Peak: $67.15 (-1.16%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $89 | +32.1% |
| 2028 | $108 | +59.6% |
| 2029 | $123 | +81.3% |
| 2030 | $133 | +97.3% |
| 2031 | — | +108.6% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · BBIO · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-05-28 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2026-05-26 | Raymond James | Downgrade ↓ | Outperform→Market Perform |
| 2026-05-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-05-08 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2026-04-29 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-04-29 | Truist Securities | Maintains | Buy→Buy |
| 2026-04-28 | Mizuho | Maintains | Outperform→Outperform |
| 2026-04-27 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-18 | Mizuho | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on BridgeBio Pharma, Inc. (BBIO) stock. Of the recent 147 rating actions, 2 were upgrades and 2 were downgrades. 26 analysts currently cover BBIO.
Analyst Recommendation Trends
BBIO analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 4 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$965M
↓ 60.5% YoY
Revenue Next Year
$1.6B
↑ 66.7% YoY
EPS This Year
$-2.18
EPS Next Year
$0.59
↓ 127.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast BBIO EPS of $-2.18 for the current fiscal year, based on estimates from 13 analysts. The BBIO revenue forecast is $965M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The BBIO stock forecast is supported by two independent data sources: analyst consensus ratings from 26 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BBIO price target is $105.21 (+55.6% upside), with an analyst consensus of Buy.
The BBIO short-term stock prediction for tomorrow is $66.83 (-1.16%). The BBIO stock price prediction for 2027 estimates an average of $89. The BBIO stock prediction for 2030 projects a range of $126–$140.
BridgeBio Pharma, Inc. trades on NASDAQ under the ticker BBIO. The BBIO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 92% of covering analysts.
Frequently asked questions
BBIO forecast · 8 questionsAccording to 26 Wall Street analysts, the average 12-month BBIO price target is $105.21, with a high forecast of $157.00 and a low of $83.00. The median price target is shown in the chart above when available. This implies +55.6% potential upside from the current price of $67.61.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.